1. Home
  2. KBDC vs PHAR Comparison

KBDC vs PHAR Comparison

Compare KBDC & PHAR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Kayne Anderson BDC Inc.

KBDC

Kayne Anderson BDC Inc.

N/A

Current Price

$13.66

Market Cap

941.8M

Sector

N/A

ML Signal

N/A

Logo Pharming Group N.V.

PHAR

Pharming Group N.V.

N/A

Current Price

$15.22

Market Cap

1.1B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
KBDC
PHAR
Founded
2021
1988
Country
United States
Netherlands
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
941.8M
1.1B
IPO Year
2018
2020

Fundamental Metrics

Financial Performance
Metric
KBDC
PHAR
Price
$13.66
$15.22
Analyst Decision
Buy
Strong Buy
Analyst Count
5
2
Target Price
$15.50
$38.00
AVG Volume (30 Days)
402.7K
19.0K
Earning Date
06-04-2026
01-01-0001
Dividend Yield
13.69%
N/A
EPS Growth
N/A
N/A
EPS
1.67
N/A
Revenue
N/A
N/A
Revenue This Year
$193.84
$27.92
Revenue Next Year
$9.00
$8.86
P/E Ratio
$8.31
$3,041.22
Revenue Growth
N/A
N/A
52 Week Low
$13.06
$7.50
52 Week High
$16.98
$21.34

Technical Indicators

Market Signals
Indicator
KBDC
PHAR
Relative Strength Index (RSI) 42.99 42.59
Support Level $13.54 $12.98
Resistance Level $14.33 $16.94
Average True Range (ATR) 0.36 0.63
MACD 0.03 0.02
Stochastic Oscillator 50.60 19.57

Price Performance

Historical Comparison
KBDC
PHAR

About KBDC Kayne Anderson BDC Inc.

Kayne Anderson BDC Inc is an externally managed, closed-end, non-diversified management investment company that has elected to be regulated as a business development company that invests primarily in first-lien senior secured loans, with a secondary focus on unitranche and split-lien loans to middle-market companies. Its investment objective is to generate current income and, to a lesser extent, capital appreciation primarily through debt investments in middle-market companies.

About PHAR Pharming Group N.V.

Pharming Group is a biopharmaceutical company focused in transforming the lives of patients with rare, debilitating, and life-threatening diseases. The company is actively developing and commercializing a diverse portfolio of innovative treatments, including both biologics and small molecule therapies. Its commercial products are RUCONEST, approved for the treatment of acute attacks in adult and adolescent patients with hereditary angioedema, or HAE; and Joenja (leniolisib), a small-molecule kinase inhibitor, developed for the treatment of activated phosphoinositide 3-kinase delta syndrome.

Share on Social Networks: